7 September 2022 - Further delays in access or complete denials of access to innovative drugs will hurt even more Canadians with unmet or poorly met health needs that could be helped by these medicines.

In April, the Federal Minister of Health announced that the Government would not proceed with two of the three major pieces in its new regulatory guidelines for the Patented Medicine Price Review Board after successive court rulings quashed changes that would have introduced complex "pharmaco-economic" calculations and require drug companies to disclose confidentially negotiated rebates.

Read The Hill Times article